Modi takes home-grown vaccine as India widens immunisation drive

India's Prime Minister Narendra Modi receives a dose of COVAXIN, developed by India's Bharat Biotech and the state-run Indian Council of Medical Research, at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, on March 1, 2021.
India's Prime Minister Narendra Modi receives a dose of COVAXIN, developed by India's Bharat Biotech and the state-run Indian Council of Medical Research, at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, on March 1, 2021.
Image: REUTERS/ India's Press Information Bureau

Indian Prime Minister Narendra Modi was inoculated with the first dose of a home-grown coronavirus vaccine on Monday, kicking off an expansion of the country's immunisation campaign that began in mid-January with health care workers.

People above 60, and those who are 45 or more and suffering from certain medical conditions, are now eligible for the vaccinations.

India, which has reported the highest number of Covid-19 cases in the world after the US, has so far vaccinated more than 12 million health and front-line workers.

“Remarkable how our doctors and scientists have worked in quick time to strengthen the global fight against Covid-19,” Modi said on Twitter, posting a picture of him getting the shot at a government hospital in New Delhi.

“I appeal to all those who are eligible to take the vaccine. Together, let us make India Covid-19 free!”

The government said last week it would let people choose their vaccination centres, effectively letting beneficiaries pick either the home-grown COVAXIN shot or the AstraZeneca vaccine, unlike earlier.

The inoculation campaign has progressed slower than expected due to a reluctance of health and front-line workers to take COVAXIN, which was approved without late-stage efficacy data. Only about 11% of vaccinated people have opted for the product developed by Bharat Biotech and the state-run Indian Council of Medical Research.

Bharat Biotech has said efficacy data from a late-stage trial on nearly 26,000 volunteers who took COVAXIN will be out soon. The company, along with India's drug regulator, says COVAXIN is safe and effective, based on early and intermediate studies.

India has reported more than 11 million coronavirus infections and over 157,000 deaths.


subscribe

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.